CR11410A - Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3 - Google Patents

Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3

Info

Publication number
CR11410A
CR11410A CR11410A CR11410A CR11410A CR 11410 A CR11410 A CR 11410A CR 11410 A CR11410 A CR 11410A CR 11410 A CR11410 A CR 11410A CR 11410 A CR11410 A CR 11410A
Authority
CR
Costa Rica
Prior art keywords
compounds
dopamine
respond
modulation
diona
Prior art date
Application number
CR11410A
Other languages
English (en)
Inventor
Wilfred Braje
Sean Colm Turner
Andreas Haupt
Udo Lange
Herve Geneste
Karla Drescher
Liliane Unger
Ana Lucia Jogen-Relo
Anton Bespalov
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11410(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of CR11410A publication Critical patent/CR11410A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona con nuevos compuestos de 1,2,4-triazin-3,5-diona, en particular con los compuestos de la formula I tal como aqui se describen. . Los compuestos poseen propiedades terapeuticas valiosas y son particularmente apropiados para tratar enfermedades que responden a la modulacion del receptor de dopamina D3.
CR11410A 2007-11-02 2010-05-03 Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3 CR11410A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119927 2007-11-02

Publications (1)

Publication Number Publication Date
CR11410A true CR11410A (es) 2010-09-13

Family

ID=40210491

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11410A CR11410A (es) 2007-11-02 2010-05-03 Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3

Country Status (29)

Country Link
US (1) US8492540B2 (es)
EP (1) EP2217593B1 (es)
JP (1) JP5559694B2 (es)
KR (1) KR20100094491A (es)
CN (1) CN101932574B (es)
AR (1) AR069150A1 (es)
AT (1) ATE556069T1 (es)
AU (1) AU2008320814B2 (es)
BR (1) BRPI0818726A2 (es)
CA (1) CA2704533C (es)
CL (1) CL2008003253A1 (es)
CO (1) CO6280473A2 (es)
CR (1) CR11410A (es)
DO (1) DOP2010000126A (es)
EC (1) ECSP10010227A (es)
ES (1) ES2386691T3 (es)
HK (1) HK1146628A1 (es)
IL (1) IL205468A0 (es)
MX (1) MX2010004830A (es)
MY (1) MY154066A (es)
NZ (1) NZ585051A (es)
PA (1) PA8802101A1 (es)
PE (1) PE20090950A1 (es)
RU (1) RU2478633C2 (es)
TW (1) TWI463984B (es)
UA (1) UA99634C2 (es)
UY (1) UY31448A1 (es)
WO (1) WO2009056625A1 (es)
ZA (1) ZA201003593B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014025993A1 (en) * 2012-08-08 2014-02-13 The Johns Hopkins University Inhibitors of d-amino acid oxidase
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
KR102643833B1 (ko) 2022-06-30 2024-03-06 현대제철 주식회사 이강종 연연주시 강종 예측 정합성 증대 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
FR2769913B1 (fr) * 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
JP2004359689A (ja) * 2003-06-05 2004-12-24 Abbott Gmbh & Co Kg ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
MX2007001530A (es) * 2004-08-09 2007-04-23 Abbott Gmbh & Co Kg Compuestos de 4-piperazinil-pirimidina adecuados para tratar trastornos que responde a la modulacion del receptor dopamina d3.
ES2417488T3 (es) 2004-12-02 2013-08-08 Abbott Gmbh & Co. Kg Compuestos de triazol adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
NZ582249A (en) * 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists

Also Published As

Publication number Publication date
MX2010004830A (es) 2010-10-20
IL205468A0 (en) 2010-12-30
ZA201003593B (en) 2011-02-23
JP2011502971A (ja) 2011-01-27
RU2010122337A (ru) 2011-12-10
AU2008320814A1 (en) 2009-05-07
PA8802101A1 (es) 2009-08-26
CN101932574A (zh) 2010-12-29
CL2008003253A1 (es) 2009-11-13
ATE556069T1 (de) 2012-05-15
AR069150A1 (es) 2009-12-30
UY31448A1 (es) 2009-05-29
EP2217593A1 (en) 2010-08-18
TWI463984B (zh) 2014-12-11
BRPI0818726A2 (pt) 2015-04-22
HK1146628A1 (en) 2011-06-24
UA99634C2 (ru) 2012-09-10
US8492540B2 (en) 2013-07-23
RU2478633C2 (ru) 2013-04-10
KR20100094491A (ko) 2010-08-26
MY154066A (en) 2015-04-30
CN101932574B (zh) 2014-07-23
DOP2010000126A (es) 2010-06-15
TW200927132A (en) 2009-07-01
CA2704533C (en) 2016-09-06
CA2704533A1 (en) 2009-05-07
CO6280473A2 (es) 2011-05-20
EP2217593B1 (en) 2012-05-02
JP5559694B2 (ja) 2014-07-23
AU2008320814B2 (en) 2013-07-11
ES2386691T3 (es) 2012-08-27
ECSP10010227A (es) 2010-08-31
US20100311755A1 (en) 2010-12-09
NZ585051A (en) 2012-03-30
PE20090950A1 (es) 2009-08-08
WO2009056625A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CO6341558A2 (es) Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos
DOP2011000081A (es) Benzamida sustituida como ligandos del receptor de canabinoides
CO6341577A2 (es) Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos
CU20110142A6 (es) Procedimiento para tratar enfermedades inflamatorias o alérgicas
HN2010002030A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
PA8841901A1 (es) Compuestos orgánicos
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
PA8777101A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
UY31432A1 (es) Compuestos de diarilhidantoina
UY33924A (es) Compuestos de triazolopiridina como inhibidores de cinasa pim
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
DOP2011000386A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
CR11187A (es) Compuestos de quinolina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6
CY1117706T1 (el) Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac
CR11410A (es) Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
DOP2010000232A (es) Derivados de indazol
UY31162A1 (es) Espiroindolinas como moduladores de receptores de quimioquinas
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CR11039A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5- ht6